Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

NCT ID	NCT02364713
Title	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Recruitment	Recruiting
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	Mayo Clinic
Indications	ovary transitional cell carcinoma fallopian tube serous adenocarcinoma peritoneum cancer ovary epithelial cancer fallopian tube transitional cell carcinoma fallopian tube endometrioid adenocarcinoma endometrioid ovary carcinoma peritoneal serous adenocarcinoma fallopian tube cancer fallopian tube mucinous adenocarcinoma ovarian clear cell carcinoma ovarian serous carcinoma fallopian tube clear cell adenocarcinoma ovarian seromucinous carcinoma ovarian mucinous neoplasm
Therapies	Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine
Age Groups:	senior \| adult
Covered Countries	USA